Non-interferon trial begins
Added: 15 September 2011
An interferon-free trial of two new drugs for all hep C genotypes has begun. Pharmasset announced that screening has begun in a Phase 2b, international study of PSI-7977 and PSI-938, two nucleotide analog polymerase inhibitors for the treatment of chronic hep C. The QUANTUM trial will evaluate interferon-free regimens of PSI-7977 and PSI-938 with and without ribavirin over 12 or 24 weeks in patients who have not been treated previously. The trial will also evaluate the use of PSI-938 monotherapy. "We are encouraged by the early efficacy and safety data being generated with our nucleotide analogs, PSI-7977 and PSI-938," stated Dr Michelle Berrey, Pharmasset's Chief Medical Officer. "The QUANTUM trial is the first interferon-free, all-nucleotide study with an SVR endpoint. The ability to include all HCV genotypes was supported by data from the NUCLEAR study and the interferon free arms of the ELECTRON trial. Data from ELECTRON are expected later this year." CLICK HERE TO GO TO ORIGINAL NEWS SOURCE>>